Recombinant Ephb4-Hsa Fusion Protein
PSA Progression
Northwestern Universityprotein_peptidePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the PSA Progression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enzalutamide Roswell Park Cancer Institute | Phase 2 | BB |
Cyclophosphamide Barbara Ann Karmanos Cancer Institute | Phase 2 | B |
Carboplatin University of Washington | Phase 2 | B |
68GA-NEOBOMB1 Andrei Iagaru | Phase 2 | B |
Psma-Hbed-Cc Jonsson Comprehensive Cancer Center | Phase 2 | B |
View all 20 →
Same molecule, other indications
Recombinant Ephb4-Hsa Fusion Protein is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →